WO2013020624A1 - Extraits de tradescantia virginiana - Google Patents

Extraits de tradescantia virginiana Download PDF

Info

Publication number
WO2013020624A1
WO2013020624A1 PCT/EP2012/002894 EP2012002894W WO2013020624A1 WO 2013020624 A1 WO2013020624 A1 WO 2013020624A1 EP 2012002894 W EP2012002894 W EP 2012002894W WO 2013020624 A1 WO2013020624 A1 WO 2013020624A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
skin
acid
plant parts
melanin
Prior art date
Application number
PCT/EP2012/002894
Other languages
German (de)
English (en)
Inventor
Corinna Wirth
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of WO2013020624A1 publication Critical patent/WO2013020624A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin

Definitions

  • the present invention relates to an extract of plant parts of Tradescantia virginiana, a process for its preparation, and its use in cosmetic and dermatological preparations.
  • the invention further relates to preparations containing an extract of plant parts of Tradescantia virginiana, and to a process for their preparation. Skin and hair color are dependent on the content, size, distribution and type of the nitrogen-containing, dark dye melanin, which is produced in the melanocyte-capable cells (melanocytes).
  • melanin is synthesized within the melanocytes.
  • melanin is transferred to the keratinocytes in the form of so-called melanosomes.
  • the melanin in the skin is a suitable protection against UV radiation, darker or over-pigmented skin may
  • melasma also called chloasma
  • chloasma irregularly shaped yellowish-brown spots.
  • freckles ephelides
  • age spots lentigines
  • Freckles are especially prone to skin type I, i. with very light skin and reddish hair.
  • Hyperpigmentation (chloasma), on the other hand, is common in those women who routinely deliver estrogen to their bodies. Very often the sun plays an important role. You can prevent it mainly by regular sunscreen with a high SPF. In order to remove unsightly pigment spots, different ones are available
  • a large number of skin-whitening compounds for the treatment of pigmentation marks are available on the market.
  • these are compounds such as e.g. Hydroquinone (1,4-dihydroxybenzene), kojic acid, arbutin, aloesin, niacinamide, vitamin C or rucinol, which suppress the production of melanin in the skin.
  • Plant extracts such as e.g. from Morus alba or Phyllanthus emblica find, especially in the Southeast Asian region, application to brighten the Hautteint.
  • UVB range wavelength 280-320 nm
  • UVA radiation wavelength: 320-400 nm
  • the epidermis contains in its lowest layer, the basal layer, in addition to the basal cells, individual pigment-forming cells, the melanocytes. UV light in these cells stimulates the production of melanin, which is transported to the keratinocytes (horny cells) where it becomes visible as a brown skin color.
  • Melanin protects the cell nuclei from further irradiation and the resulting negative effects on the cell DNA.
  • Pigments are distinguished between the brownish-black eumelanin and the reddish-yellow pheomelanin.
  • the observed skin tone is determined by the ratio of these two types of melanin.
  • keto or aldehyde groups in the vicinity of alcohol functions and belong predominantly to the substance class of sugars.
  • Particularly commonly used self-tanning substances are 1,3-dihydroxyacetone (DHA), used in an amount of 700 t / a, and erythrulose.
  • DHA 1,3-dihydroxyacetone
  • Classic self-tanning agents can be reacted with the proteins and amino acids of the horny layer of the skin in the sense of a Maillard reaction or via a Michael addition, whereby polymers which give the skin a brownish hue emerge via a not yet fully elucidated reaction pathway. This reaction is completed in about 4 to 6 hours. The tan thus obtained is not washable and is removed only with the normal Hautabschuppung.
  • Sunscreen (clothing, hat, UV filter) is required.
  • the tanned skin In contrast to "tanned" skin, the tanned skin is not protected against sunburn.
  • Skin-staining substances which are suitable for use in cosmetic and / or dermatological preparations or medical products and which enhance the natural tanning of the skin by increasing the synthesis of melanin and at the same time better skin protection or
  • Sun protection especially against UVB radiation allow. It is an object of the present invention to provide novel agents that affect the appearance and hue of the skin by acting as a self-tanning or skin whitening agent.
  • Extraction conditions both have a high skin lightening effect and can act as a self-tanning agent.
  • self-tanning active is used synonymously with self-tanning substance, self-tanner or self-tanning substance.
  • Tradescantia virginiana is a herbaceous plant that is planted in gardens for ornamental purposes. It is also used in bioassays to test the presence of ionizing radiation, which causes its stamens to turn red.
  • plant hybrids of Tradescantia virginiana are also included, i. Plants derived from a cross of Tradescantia virginiana with another species or subspecies of the genus Tradescantia.
  • JP 2009040753 describes skin-repairing compositions containing plant extracts of Tradescantia spathacea.
  • DE 102007042009 A1 describes pharmaceutical formulations which, inter alia, can also be used for the treatment of skin diseases and contain an extract of Tradescantia spathacea.
  • a first subject of the present invention is therefore an extract of plant parts of Tradescantia virginiana.
  • Plant parts preferably used for extraction are the leaves or flowers or mixtures thereof, more preferably the leaves are used.
  • the plant extract of Tradescantia virginiana can be prepared by methods known to those skilled in the art.
  • a plant extract which is particularly suitable for the use according to the invention is obtainable by a) extraction of the plant parts of Tradescantia virginiana with the aid of a solvent and, optionally, b) removal of the solvent.
  • a process for producing an extract from plant parts of Tradescantia virginiana comprising the steps of a) extraction of the plant parts of Tradescantia virginiana with the aid of a solvent and, optionally, b) removal of the solvent.
  • the plant parts can be used directly for the extraction according to step a). Typically, however, the plant parts are first dried and crushed.
  • the drying can be carried out, for example, in air or preferably in a drying oven at elevated temperature, preferably between 30 and 50 ° C, more preferably at about 40 ° C. In addition, the drying can also be carried out under reduced pressure.
  • the crushing can be done by common methods, for example by using cutting tools such as knives or scissors, or by using a blender. For larger quantities, mills such as hammer mills can be used.
  • the plant parts are extracted.
  • the extraction is carried out by methods known to those skilled in the art.
  • the plant parts are typically mixed with a solvent.
  • a solvent selected from water, organic solvents or mixtures thereof.
  • organic solvents are methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, acetone or ethyl acetate.
  • Solvent mixtures of water and organic solvents preferably contain 0-90% by volume of water, particularly preferably 30-70% by volume of water.
  • the solvent is selected from water or alcohol.
  • an alcohol in particular ethanol, is used as solvent.
  • water is used as the solvent.
  • the extraction is typically carried out at temperatures between 20 and 90 ° C, preferably between 50 and 90 ° C, more preferably at the boiling point of the solvent or solvent mixture. This means that when using water as a solvent the
  • Extraction is particularly preferably carried out at about 00 ° C, while the extraction is particularly preferably carried out at about 78 ° C when using ethanol as a solvent.
  • the solvent is removed. This is typically done by filtration.
  • the method also comprises step b).
  • the resulting extract may optionally be further purified. All methods familiar to the person skilled in the art can be used for this purpose, for example chromatographic methods such as solid phase adsorption with subsequent stepwise desorption by means of suitable solvents. The chromatography can also be carried out in countercurrent. Concentration and enrichment can also take place by means of supercritical gases or ionic liquids. It is also possible by liquid / liquid extraction to deplete unwanted
  • the dry extract obtained is usually taken up in a little water and extracted with a further solvent, such as heptane. Unless it is a
  • This water extract can also be purified as a concentrated crude extract directly (without further addition of water) with another solvent in a liquid / liquid extraction. Even by changing the solvent with subsequent filtration unwanted components can be removed.
  • the extract obtained can then be concentrated and / or dried in a step c).
  • Rotary evaporator or a falling film evaporator and can also be done under reduced pressure.
  • the extract can be dried, for example, by means of spray drying or freeze drying.
  • the extract is preferably dried completely to constant weight.
  • Another object of the present invention is the use of an extract from plant parts of Tradescantia virginiana, as described above, in cosmetic or dermatological preparations. In a preferred embodiment, the use for
  • a particularly preferred embodiment of the present invention is the use of an extract from plant parts of Tradescantia virginiana for the inhibition of melanin synthesis, for the prophylaxis, treatment and / or follow-up of pigmentary disorders of the skin.
  • Inhibition of melanin synthesis can be accomplished, for example, by regulation of the transcription or activity of tyrosinase (e.g., inhibition or degradation of tyrosinase), TRP-1 (tyrosinase related protein), TRP-2 (tyrosinase related protein-2), and / or peroxidase. This is also possible in vitro.
  • the term “inhibition” refers to any reduction in activity based on the action of the specific extract of the invention and by recognition, binding and blocking of the activity
  • Target molecules is enabled.
  • the aforementioned use of the extract can be done in in vitro or in vivo models.
  • the susceptibility of a particular cell to treatment with the extract can be determined by testing in vitro.
  • a culture of the cell with the Extract of the invention is incubated at various concentrations for a period of time sufficient to allow the active agents to inhibit the synthesis of melanin, usually between about one hour and one week.
  • Cultured cells from a biopsy sample can be used for testing in vitro.
  • the amount of post-treatment melanin in the cells is then determined.
  • the use in vitro is carried out in particular on samples of
  • Mammalian species that suffer from skin pigmentation disorders may be of any mammalian species, e.g. B. one
  • mice including mice, rats and hamsters
  • rabbits horses, cattle, dogs, cats, etc.
  • the in vivo dose of the extract is advantageously matched to the susceptibility of the tyrosinase and / or severity of the patient's pigmentation disorder with respect to the in vitro data, thereby significantly increasing efficacy.
  • a cosmetic dose will be sufficient to significantly reduce the undesirable amount of melanin in the target tissue while maintaining and ultimately improving the patient's quality of life.
  • Use will generally continue until there is a significant reduction in tyrosinase activity and / or melanin production, e.g. at least about 10% reduction in melanin content and can be continued until essentially no undesirable
  • extracts of plant parts of Tradescantia virginiana are furthermore for use in prophylaxis, treatment and / or follow-up of pigment disorders which
  • Inhibition of melanin synthesis can generally also be achieved by regulation of skin lightening
  • Receiver keratinocytes the breakdown of melanin or melanosomes or the detachment of pigmented keratinocytes happen.
  • the skin-lightening effect of the extract is particularly good when it is prepared by the method described above and in particular according to its preferred embodiments.
  • step a) of the process according to the invention as described above, water is used as solvent.
  • the use of the extract according to the invention takes place as a self-tanning agent.
  • Extracts from plant parts of Tradescantia virginiana can therefore also have very good browning properties.
  • this is preferably the use for increasing melanin synthesis, improving melanin transport and / or improving the distribution of melanin in suprabasal
  • the extracts according to the invention increase the melanin synthesis and improve the melanin transport from the melanocytes to the
  • Keratinocytes This affects the color of the skin and causes a tanning effect.
  • the extracts according to the invention act as biological self-tanning agents, i. as a melanogenesis promoter or
  • extracts according to the invention is due to a combination of different active components in the extracts.
  • the tanning action of the extract is particularly good when used according to the method described above, and in particular according to their
  • Alcoholic extracts from plant parts of Tradescantia virginiana are particularly suitable as self-tanning agents, ie extracts in the preparation of which in step a) of the process according to the invention, as described above, an alcohol is used as solvent.
  • the extracts are also characterized by a high
  • dermatological especially dermatological, nature. It is preferably a cosmetic use, more preferably a non-therapeutic cosmetic use.
  • Another object of the present invention is a preparation containing an extract of plant parts of Tradescantia virginiana as described above.
  • the preparations are usually topically applicable preparations, for example cosmetic or cosmetic preparations
  • compositions in this case contain a cosmetically or dermatologically suitable carrier and, depending on the desired
  • compositions in this case contain a pharmaceutically acceptable carrier and optionally further pharmaceutical active ingredients. It is preferably a cosmetic or pharmaceutical preparation; most preferably it is a cosmetic preparation.
  • preparation is synonymous with the term “agent”, “composition” or “formulation” used.
  • Topically applicable means according to the invention that the preparation is applied externally and locally, ie that the preparation must be suitable in order to be applied to the skin, for example.
  • the preparations may contain the necessary or optional
  • Components include, contain, consist essentially of, or consist of. Any compounds or components which may be used in the compositions are either known and commercially available or may be synthesized by known methods.
  • the preparations according to the invention preferably contain from 0.01 to 99% by weight of the extract of plant parts of Tradescantia virginiana, based on the total weight of the preparation. Preference is given to using an amount of from 0.05 to 30% by weight, more preferably from 0.1 to 10% by weight. The expert does not have any difficulties in selecting the quantities according to the intended effect of the preparation.
  • compositions according to the invention may contain further ingredients.
  • Preferred preparations according to the invention may contain at least one self-tanning substance as further ingredient.
  • This can be either a self-tanner, which reacts with the amino acids of the skin in the sense of a Maillard reaction or via a Michael addition, as well as a so-called melanogenesis promoter or Propigment michswirkstoff that promotes the natural tanning of the skin.
  • Advantageous self-tanning substances which can be used include: 1,3-dihydroxyacetone, glycerolaldehyde,
  • propigmentation substances can be all active ingredients known to the person skilled in the art. Examples include glycyrrhetinic acid, melanocyte-stimulating hormone (alpha-MSH), peptide analogues, thymidine
  • the at least one self-tanning substance is in the
  • Preparation in an amount of 0.01 to 20 wt .-%, particularly preferably in an amount of 0.5 to 15 wt .-% and most preferably in an amount of 1 to 8 wt .-%, based on the total amount the preparation included.
  • the extract according to the invention already has a skin-tanning effect on its own (for example, if it is an alcoholic extract), the preparation according to the invention which has a skin tanning effect
  • the tanning achieved is close to the natural tanning
  • the extract according to the invention itself has a skin-lightening effect (for example a water extract)
  • a corresponding preparation which combines the extract and a self-tanning substance generally has a contrast-reducing effect and makes it possible to achieve an even skin tone.
  • the extracts of plant parts of Tradescantia virginiana can also be used according to the invention in combination with self-tanning substances for the purpose of reducing the contrast and achieving an even skin tone.
  • a contrast reducing agent is a substance that reduces uneven skin coloration by reducing the contrast between stronger and less-colored areas of the skin. In this case, such an uneven skin coloration can be caused by an uneven pigmentation and / or a different distribution of the cornea. Uneven pigmentation is by no means uncommon in the population and is due to a different degree of melanin production of the melanocytes or an irregular distribution of the melanocytes in the skin.
  • melanogenesis inhibiting substances already causes
  • hyperpigmented skin areas lose their high melanin concentrations and the hue generated by the colorant on the skin surface is widely spread.
  • a contrast reduction can be achieved in particular by preparations in which an extract of plant parts of Tradescantia virginiana with a self-tanning substance, preferably
  • DHA Dihydroxyacetone
  • Self-tanning substances preferably containing DHA, DHA rapid, DHA plus and / or erythrulose.
  • Self-tanning agents in a mixture or preparation containing dihydroxyacetone may be used inter alia: glycerolaldehyde, hydroxymethylglyoxal, ⁇ -dialdehyde, 6-aldo-D-fructose, ninhydrin, 5-hydroxy-1,4-naphthoquinone (juglone) or 2-hydroxy-1 , 4-naphthoquinone (Lawson) or a mixture of said compounds.
  • Erythrulose is particularly preferably used in the mixture containing dihydroxyacetone. Very particular preference is given to using dihydroxyacetone or a derivative derived therefrom without further self-tanning substances.
  • the preparations according to the invention may also contain at least one active substance or extract with a skin-lightening activity. If the extract according to the invention itself has a skin-lightening effect, the addition of a further skin-lightening active substance can enhance the skin-healing effect.
  • Skin-lightening active ingredients or synonymously depigmenting agents which can be used in the preparations according to the invention can, in principle, be all active ingredients known to the person skilled in the art.
  • melanogenesis inhibitors such as, for example, ascorbic acid and its derivatives, aloesin, niacinamide, emblica, elagic acid, licorice extract, mulberry tree extract, kojic acid, licorice root extract, rucinol, hydroquinone and its derivatives, azelaic acid, arbutin, magnesium ascorbyl phosphate, pantothenic acid and their derivatives or salts, Glucosamine and its derivatives, mercaptoamines, hinokitol, tocopherols, ubiquinones, glabridin, 4-hydroxyanisole, 4-tert-butylphenol, resveratrol, 4-S-cystaminylphenol, glutathione, lactic acid or the like.
  • Preferred examples of compounds having skin-lightening activity are
  • Preferred examples of extracts with skin-lightening activity are licorice extract, mulberry extract or emblica.
  • the preparations according to the invention can also be used in addition to
  • Extracts according to the invention also additionally contain at least one UV filter.
  • Sunscreen filters are effective in the UVA range and / or UVB range and / or IR and / or VIS range (absorber). These substances can be obtained, in particular, from cinnamic acid derivatives, salicylic acid derivatives,
  • UV filters are usually named according to the INCI nomenclature. In particular suitable for a combination are:
  • PABA para-aminobenzoic acid and its derivatives: PABA, ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA, e.g. B. sold under the name "Escalol 507" from the company.
  • ISP glyceryl PABA, PEG-25 PABA, z. B. sold under the name "Uvinul P25” from the company.
  • BASF para-aminobenzoic acid and its derivatives: PABA, ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA, e.g. B. sold under the name "Escalol 507" from the company.
  • ISP glyceryl PABA, PEG-25 PABA, z. B. sold under the name "Uvinul P25” from the company.
  • BASF para-aminobenzoic acid and its derivatives: PABA
  • Salicylates Homosalates are sold under the name "Eusolex HMS” by Merck; Ethyl hexyl salicylates, e.g. B. sold under the name “Neo Heliopan OS "from Symrise, Dipropylene glycol salicylate, for example sold under the name” Dipsal "by the company Scher, TEA salicylate, for example sold under the name” Neo Heliopan TS “by the company.
  • Benzophenone-6 e.g. B. marketed under the name "Helisorb 1" by the company.
  • Benzylidene camphor derivatives 3-benzylidenecamphor, e.g. Sold under the name “Mexoryl SD” from the company. Chimex, 4-Methylbenzylidenecamphor, z. Sold under the name "Eusolex
  • Mexoryl SL from the company Chimex, Camphor
  • benzalkonium methosulfates e.g. Sold under the name "Mexoryl SO” from the company. Chimex, Terephthalylidenedicamphorsulfonklare, z. Sold under the name "Mexoryl SX” by Chimex,
  • Phenylbenzimidazole derivatives phenylbenzimidazole fatty acid, e.g. B.
  • Phenylbenzotriazole derivatives Drometrizole trisiloxanes, e.g. B. marketed under the name “Silatrizole” by the company. Rhodia Chimie,
  • Methylenebis (benzotriazolyl) tetramethylbutylphenol in solid form e.g. B. marketed under the name "MIXXIM BB / 100" from the company. Fairmount Chemical, or in micronized form as an aqueous dispersion, eg. B.
  • Triazine derivatives ethylhexyltriazone, e.g. B. sold under the name "Uvinul T150" from the company. BASF, Diethylhexylbutamidotriazone, z. B.
  • menthyl anthranilate e.g. B. sold under the
  • Imidazole derivatives ethylhexyldimethoxybenzylidenedioxoimidazoline
  • Benzalmalonate Derivatives Polyorganosiloxanes containing functional benzalmalonate groups, such as polysilicone-15, z. Sold under the name "Parsol SLX" by Hoffmann LaRoche. 4,4-Diarylbutadiene Derivatives: 1,1-Dicarboxy (2,2'-dimethylpropyl) -4,4-diphenylbutadiene.
  • Benzoxazole derivatives 2,4-bis [5- (1-dimethylpropyl) benzoxazol-2-yl (4-phenyl) imino] -6- (2-ethylhexyl) imino-1,3,5-triazines, e.g. B. sold under the name Uvasorb K2A from the company. Sigma 3V and mixtures containing this.
  • Pi erazine derivatives such as the compound
  • UV filters are specific. Of course, other UV filters can be used.
  • Suitable organic UV-protective substances are preferably to be selected from the following list: ethylhexyl salicylate,
  • Phenylbenzimidazolesulfonic acid benzophenone-3, benzophenone-4, benzophenone-5, n-hexyl 2- (4-diethylamino-2-hydroxybenzoyl) benzoate, 4-methylbenzylidenecamphor, terephthalylidenedicamphorsulfonic acid, disodium phenyldibenzimidazoletetrasulfonate,
  • the preparations may contain, in addition to the extracts according to the invention and the optionally organic UV filters, as described above, further inorganic UV filters, so-called particulate UV filters.
  • coated titanium dioxide e.g., Eusolex® T-2000, Eusolex® T-AQUA,
  • Eusolex® T-AVO Eusolex® T-OLEO
  • zinc oxides e.g., Sachtotec®
  • Iron oxides or else cerium oxides and / or zirconium oxides are preferred.
  • Zinc oxide is possible, the particle size of these pigments being greater than or equal to 200 nm, for example Hombitan® FG or Hombitan® FF-Pharma.
  • the preparations may further be preferred if the preparations contain inorganic UV filters which are prepared by customary methods, such as, for example, in US Pat
  • one or more of the following aftertreatment components may be selected: amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids,
  • fatty acids fatty acid alcohols, anionic surfactants, lecithin, phospholipids, sodium, potassium, zinc, iron or aluminum salts of Fatty acids, polyethylenes, silicones, proteins (especially collagen or elastin), alkanolamines, silica, alumina, other metal oxides, phosphates, such as sodium hexametaphosphate or glycerol.
  • Preferably used particulate UV filters are:
  • untreated titanium dioxides e.g. the products Microtitanium Dioxide MT 500 B from Tayca; Titanium Dioxide P25 from Degussa,
  • Silica post-treatment such as e.g. the product "Microtitanium Dioxide MT 100 SA of Tayca; or the product “Tioveil Fin” from Uniqema,
  • micronised titanium dioxides with alumina and / or aluminum stearates / laurate aftertreatment such as e.g. Microtitanium Dioxide MT 100 T from Tayca, Eusolex T-2000 from Merck,
  • Iron stearates aftertreatment such as e.g. the product "Microtitanium Dioxide MT 100 F" from Tayca,
  • Alumina and silicone aftertreatment such as e.g. the product "Microtitanium Dioxide MT 00 SAS", the company Tayca,
  • the treated micronized titanium dioxides used for combination may also be post-treated with:
  • Aluminum and silicone oils e.g. the product UV titanium M262 of the Fa.
  • Polydimethylsiloxanes e.g. the product 70250 Cardre UF Ti02SI3 "from the company Cardre,
  • Escalol Z100 from ISP (alumina aftertreated ZnO dispersed in an ethylhexyl methoxycinnamate / PVP-hexadecenes / methicone copolymer blend)
  • Fuji ZNO-SMS-10 from Fuji Pigment (ZnO aftertreated with silica and polymethylsilsquioxane);
  • mixtures of various metal oxides e.g. Titanium dioxide and cerium oxide with and without Nachbenmaschine be used, such. the product Sunveil A of the company Ikeda.
  • These inorganic UV filters are usually incorporated in the formulations in an amount of from 0.1 percent by weight to 25 percent by weight, preferably from 2 percent by weight to 10 percent by weight.
  • UV filters can also be used in encapsulated form.
  • organic UV filters it is beneficial to use organic UV filters in
  • the capsules in preparations to be used according to the invention are preferably present in amounts which ensure that the encapsulated UV filters in the abovementioned
  • Weight percent ratios are present in the preparation.
  • color pigments may furthermore furthermore be present, the layer structure of the pigments not being limited.
  • the color pigment when used from 0.5 to 5 wt .-% should be skin-colored or brownish.
  • Pigments is familiar to the skilled person.
  • At least one further active ingredient can be present in the preparations according to the invention.
  • the further active ingredient is preferably selected from the group of antioxidants, vitamins, anti-aging agents, anti-inflammatory agents, antimicrobial
  • Active ingredients active ingredients for improving the moisture content of the skin (skin moistness regulators), anti-cellulite active ingredients, anti-wrinkle agents, anti-dandruff agents, anti-acne agents, deodorants and pigments, particularly preferably from the group of antioxidants, vitamins , Anti-aging agents and anti-cellulite agents, most preferably from the group of antioxidants and vitamins.
  • the protective effect of preparations against oxidative stress or against the action of radicals can be improved if the preparations contain one or more antioxidants, wherein the skilled person has no difficulty in selecting suitable fast or delayed-acting antioxidants.
  • imidazoles eg urocaninic acid
  • peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg anserine)
  • carotenoids eg a- Carotene, ⁇ -carotene, lycopene
  • carotenes eg a- Carotene, ⁇ -carotene,
  • Aurothioglucose, propylthiouracil and other thiols eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl , ⁇ -linoleyl, cholesteryl and glyceryl esters
  • thiols eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl , ⁇ -linoleyl, cholesteryl and glyceryl esters
  • Dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives esters, ethers, peptides, lipids, nucleotides, nucleosides and salts
  • sulfoximine compounds for example buthionine sulfoximines
  • Heptathionine sulfoximine in very low tolerated dosages (e.g., pmol to pmol / kg), further (metal) chelators (e.g., ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • Citric acid lactic acid, malic acid), humic acid, bile acid,
  • ethylenediaminetetramethylene phosphonate and its derivatives unsaturated fatty acids and their derivatives, vitamin C and derivatives (e.g.
  • Ascorbyl palmitate magnesium ascorbyl phosphate, ascorbyl acetate
  • Tocopherol and derivatives e.g., vitamin E acetate
  • vitamin A and derivatives e.g., vitamin A palmitate
  • benzoic acid coniferyl benzoate rutinic acid and derivatives thereof, ⁇ -glycosyl rutin, ferulic acid
  • Selenethethionine silibens and their derivatives (e.g., stilbene oxide, trans-stilbene oxide).
  • Suitable antioxidants are also compounds of the formulas A or B.
  • R can be selected from the group -C (O) CH 3 , -CO 2 R 3 , -C (O) NH 2 and -C (O) N (R) 2
  • X is O or NH
  • R 2 is linear or branched alkyl having 1 to 30 C atoms
  • R 3 is linear or branched alkyl having 1 to 20 C atoms
  • R 4 each independently of one another are H or linear or branched alkyl having 1 to 8 C atoms
  • R 5 H linear or branched alkyl having 1 to 8 carbon atoms or
  • R 6 denotes linear or branched alkyl having 1 to 8 C atoms, preferably derivatives of 2- (4-hydroxy-3,5-dimethoxybenzylidene) malonic acid and / or 2- (4-hydroxy-3,5-dimethoxybenzyl) - malonic acid, more preferably 2- (4-hydroxy-3,5-dimethoxybenzylidene) -malonic acid bis (2-ethylhexyl) ester (eg Oxynex® ST Liquid) and / or 2- (4-hydroxy-3,5-dimethoxybenzyl ) -malonic acid bis (2-ethylhexyl) ester (eg RonaCare® AP).
  • antioxidants are also suitable for use in the formulations of the invention.
  • Known and purchasable Mixtures are, for example, mixtures containing as active
  • Citric acid e.g., Oxynex® K LIQUID
  • tocopherol extracts e.g., tocopherol extracts
  • L - (+) - ascorbyl palmitate L - (+) - ascorbic acid and citric acid
  • DL-a-tocopherol L (+) - ascorbyl palmitate
  • citric acid and lecithin eg Oxynex® LM
  • BHT butylhydroxytoluene
  • L - (+) - ascorbyl palmitate and citric acid eg Oxynex® 2004.
  • antioxidants are used in the
  • compositions according to the invention usually in amounts of
  • 0.1 to 20 wt .-% preferably used in amounts of 0.1 to 10 wt .-%.
  • the polyphenols which occur in part as natural substances, are of particular interest for applications in the pharmaceutical, cosmetic or nutritional field.
  • the flavonoids or bioflavonoids which are mainly known as plant dyes, frequently have an antioxidant potential.
  • Quercetin (cyanidanol, cyanidolone 1522, meietin,
  • effective antioxidant e.g., CA. Rice-Evans, N.J. Miller, G.
  • Preparations are preferably so-called compatible solutes. These are substances that are involved in the osmoregulation of
  • osmolytes Plants or microorganisms are involved and can be isolated from these organisms. Under the generic term compatible solutes also the described in the German patent application DE-A-10133202 osmolytes are taken. Suitable osmolytes are, for example, the polyols, methylamine compounds and amino acids and in each case their precursors. As osmolytes are in the sense of the Germans
  • Patent application DE-A-10133202 especially substances from the group of polyols, such as myo-inositol, mannitol or sorbitol and / or understood one or more of the following osmolytically active substances: taurine, choline, betaine, phosphoryicholine, Glycerophosphorylcholine, glutamine, glycine , ⁇ -alanine, glutamate, aspartate, proline, and taurine.
  • Precursors of these substances are, for example, glucose, glucose polymers, phosphatidylcholine, phosphatidylinositol, inorganic phosphates, proteins, peptides and polyamic acids. Precursors are z. B.
  • compatible solute substances selected from the group consisting of Pyrimidincarbonklaren (such as ectoine and hydroxyectoine), proline, betaine, glutamine, cyclic
  • Diphosphoglycerate N. acetylornithine, trimethylamine N-oxide di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1, 1-diglycerol phosphate (DGP), ⁇ -mannosylglycerate (Firoin) , ß-
  • Mannosylglyceramide (Firoin-A) or / and di-mannosyl-di-inositol phosphate (DMIP) or an optical isomer, derivative, for example an acid, a salt or ester of these compounds or combinations thereof.
  • DMIP di-mannosyl-di-inositol phosphate
  • pyrimidinecarboxylic acids in particular, ectoine ((S) -I- ⁇ -tetrahydro-Z-methyl-pyrimidinecarboxylic acid) and hydroxyectoine ((S, S) -1, 4,5,6-tetrahydro-5-hydroxy 2-methyl-4-pyrimidinecarboxylic acid) and their derivatives.
  • Ronacare® tiliroside or Ronacare® cyclopeptide 5 can be used.
  • compositions to be used may be further ingredients
  • vitamins and vitamin derivatives selected from vitamin A, vitamin A propionate, vitamin A palmitate, vitamin A acetate, retinol, vitamin B, thiamin chloride hydrochloride (vitamin Bi), riboflavin (vitamin B 2 ), nicotinamide, Vitamin C (ascorbic acid), vitamin D, ergocalciferol (vitamin D 2 ), vitamin E, DL-a-tocopherol, tocopherol-E-acetate, tocopherol hydrogen succinate, vitamin K 1 t esculin (vitamin P active ingredient), thiamine (vitamin B, Nicotinic acid (niacin),
  • Vitamins are usually added to the flavonoid-containing premixes or preparations when applied cosmetically in the range of 0.01% to 5.0% by weight, based on the total weight.
  • the described retinoids are also effective anti-cellulite agents.
  • Another well-known anti-cellulite drug is caffeine.
  • Another embodiment of the present invention relates to a pharmaceutical composition containing an extract of plant parts of Tradescantia virginiana. A "drug”, "drug” as well as a "pharmaceutical
  • compositions pharmaceutical formulations
  • “Pharmaceutical preparation” here is any agent which in the prophylaxis, therapy, follow-up or treatment of
  • Patients can be used, at least temporarily show a pathogenic modification of the overall condition or the condition of individual parts of the patient's organism, preferably as a result of pigmentation of the skin.
  • Adjuvants are added.
  • any substance which makes possible an action with the extracts according to the invention enhances or modifies an "adjuvant.”
  • Known adjuvants are, for example, aluminum compounds such as aluminum hydroxide or aluminum phosphate, saponins such as QS 21, muramyl dipeptide or
  • the introduction of the pharmaceutical agent into a cell or an organism can be done according to the invention in any way.
  • the pharmaceutical agent of the present invention may be administered orally, topically, transdermally, transmucosally, transurethally, vaginally, rectally, pulmonarily, enterally and / or parenterally, preferably topically or transdermally.
  • the chosen mode of administration depends on the indication, the dose to be administered, the individual specific parameters, etc. In particular, the different modes of administration allow for site-specific therapy
  • the dosage forms of the pharmaceutical agent are prepared with the usual solid or liquid carriers and / or diluents and the commonly used excipients according to the desired mode of administration in a suitable dosage and in a conventional manner.
  • pharmaceutically acceptable excipients known to those skilled in the art may form part of the pharmaceutical composition of the present invention wherein the amount of excipient material combined with the active ingredient is one
  • Single dose varies depending on the individual to be treated and the mode of administration.
  • These pharmaceutically acceptable additives include salts, buffers, fillers, stabilizers, chelants, antioxidants, solvents, binders, lubricants, tablet coatings, flavors, colors, preservatives, sizing agents, and the like.
  • excipients are water, vegetable oils, benzyl alcohols, alkylene glycol, polyethylene glycol,
  • Glycerol triacetate Glycerol triacetate, gelatin, carbohydrates, e.g. Lactose or starch, magnesium stearate, talc and Vaseline.
  • the pharmaceutical formulation may be in the form of tablet, film-coated tablet, dragee, lozenge, capsule, pill, powder, granule, syrup, juice, drops, solution, dispersion, suspension, suppository, emulsion, implant, cream, gel, ointment, paste, lotion, serum , Oil, spray, aerosol, glue, plaster or dressing.
  • the oral dosage form used is preferably tablets, film-coated tablets, dragees, lozenges, capsules, pills, powders, granules, syrups, juices, drops, solutions, dispersions or
  • parenteral dosage forms such as e.g. Suppositories, suspensions,
  • the active pharmaceutical ingredient is at least one pharmaceutical
  • a acceptable carrier e.g. microcrystalline cellulose
  • excipients such as e.g. Moisturizers
  • skin solid formulations such as Creams, gels, ointments, pastes, powders or emulsions, or to skin-applied liquid formulations, e.g. Solutions, suspensions, lotions, serums, oils, sprays or aerosols formulated in a conventional manner.
  • the pharmaceutical agent is for topical application.
  • the pharmaceutical agent may also be present as a solid composition, for example in the lyophilized state, and then by addition of a dissolving agent, such as e.g. distilled water, before the
  • Lyophilisates are familiar to the skilled worker.
  • the concentration of the extract in the formulation may be from 0.01 to 99% by weight. It is crucial that the pharmaceutical composition comprises as active ingredient an effective amount of the extract together with the pharmaceutically acceptable excipients.
  • effective amount or “effective dose” are used herein
  • prophylactic effect prevents the onset of a disease and includes an increase in the normal physiological function prophylaxis is particularly advisable when an individual has predispositions for the onset of the aforementioned diseases, such as a family history, a genetic defect or a recent Illness, one
  • “Therapeutically relevant effect” partially or completely relieves one, several or all disease symptoms or leads to the partial or complete return of one, several or all physiological or biochemical parameters associated with or causative of the disease or pathological alteration.
  • follow-up is understood as a type of therapeutic treatment when the extract is administered at certain intervals, eg to completely eliminate the symptoms of a disease.
  • the particular dose or range of administration for the dose is large enough to achieve the desired prophylactic or therapeutic effect of inducing a biological or medical response. In general, the dose will vary with the age, constitution and gender of the patient, as well as the severity of the disease. It is understood that the specific dose, frequency and duration of administration of a variety of
  • the individual dose can be adjusted both in relation to the primary illness and in relation to the occurrence of possible complications.
  • the exact dose is through one
  • the pharmaceutical composition in order to promote the medicinal effect, may also comprise one or more further active ingredients, simultaneous or sequential administration being conceivable.
  • the therapeutic effect of the pharmaceutical composition according to the invention may be, for example, that the inhibition of the
  • the present invention also provides a process for the preparation of a preparation as hereinbefore described
  • the extract of plant parts of Tradescantia virginiana is mixed with a carrier suitable for topical applications.
  • the mixing can also be carried out with other auxiliaries and / or fillers. Suitable excipients and auxiliaries or fillers are described in detail in the following part.
  • the said constituents of the preparation can be incorporated in the usual way, by means of techniques which are well known to the person skilled in the art.
  • the mixing can be a dissolving, emulsifying or
  • the cosmetic and dermatological preparations can be in various forms. So they can z.
  • a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) type or of the oil-in-water (O / W) type a multiple emulsion, for example of the Waser-in type.
  • Oil-in-water (W / OW) or OW / O a gel, a solid stick, an ointment or even an aerosol.
  • Preference is given to emulsions. O / W emulsions are particularly preferred.
  • Emulsions, W / O emulsions and O / W emulsions are available in the usual way.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin in a sufficient amount in the manner customary for cosmetics.
  • solutions solutions, suspensions, emulsions, PIT emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing
  • Application forms are e.g. Sticks, shampoos and shower baths. Further, typical cosmetic applications include lipsticks, lip balms, powder, emulsion and wax make-up as well
  • Preferred excipients come from the group of preservatives, stabilizers, solubilizers, colorants, i. Pigments / dyes, emulsifiers or odor improvers.
  • Ointments, pastes, creams and gels may contain the usual excipients suitable for topical administration, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth,
  • Cellulose derivatives Polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.
  • Powders and sprays may contain the usual carriers, e.g.
  • Sprays may additionally contain the usual volatilized, liquefied propellants, e.g.
  • Chlorofluorocarbons propane / butane or dimethyl ether. Also, compressed air is advantageous to use.
  • Solutions and emulsions may be the usual carriers such as
  • Solvents, solubilizers and emulsifiers for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, XTend 226 (L'Oreal) , Glycerin fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
  • a preferred solubilizer in general is 2-isopropyl-5-methylcyclohexanecarbonyl-D-alanine methyl ester.
  • Suspensions may be the usual carriers such as liquid
  • Diluent e.g. Water, ethanol or propylene glycol
  • Suspending agent e.g. ethoxylated isostearyl alcohols
  • Polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.
  • Soaps may contain the usual excipients such as alkali metal salts of fatty acids, salts of fatty acid monoesters, fatty acid protein hydrolysates, isothionates, lanolin, fatty alcohol, vegetable oils, plant extracts, glycerol, sugars or mixtures of these substances.
  • excipients such as alkali metal salts of fatty acids, salts of fatty acid monoesters, fatty acid protein hydrolysates, isothionates, lanolin, fatty alcohol, vegetable oils, plant extracts, glycerol, sugars or mixtures of these substances.
  • Surfactant-containing cleaning products the usual carriers such as salts of fatty alcohol sulfates, fatty alcohol ether sulfates,
  • Sulfosuccinic monoesters fatty acid protein hydrolysates, isothionates, imidazolinium derivatives, methyltaurates, sarcosinates,
  • Fatty acid diethanolamides vegetable and synthetic oils, lanolin derivatives, ethoxylated glycerol fatty acid esters or mixtures of these substances.
  • Facial and body oils may contain the usual carriers such as synthetic oils such as fatty acid esters, fatty alcohols, silicone oils, natural oils such as
  • Vegetable oils and oily vegetable extracts, paraffin oils, lanolin oils or mixtures of these substances are particularly useful as vegetable oils and oily vegetable extracts, paraffin oils, lanolin oils or mixtures of these substances.
  • the preferred preparation forms include in particular
  • Emulsions which is present as cream or milk and contain z.
  • oily lotions based on natural or synthetic oils and waxes, lanolin,
  • Fatty acid esters in particular triglycerides of fatty acids, or oily alcoholic lotions based on a lower alcohol, such as ethanol, or a glycerol, such as propylene glycol, and / or a polyol, such as glycerol, and oils, waxes and fatty acid esters, such as triglycerides of fatty acids.
  • the preparation may also be in the form of an alcoholic gel comprising one or more lower alcohols or polyols, such as ethanol, propylene glycol or glycerin, and a thickener, such as silica.
  • the oily alcoholic gels also contain natural or synthetic oil or wax.
  • the solid sticks consist of natural or synthetic waxes and oils, fatty alcohols, fatty acids, fatty acid esters, lanolin and other fatty substances.
  • blowing agents are generally used, such as alkanes, air, nitrogen, dinitrogen monoxide, preferably alkanes or air.
  • Oils such as triglycerides of capric or caprylic acid, also natural oils such. Castor oil;
  • esters of fatty acids with alcohols of low C number eg with isopropanol, propylene glycol or glycerol, or esters of
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes,
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the context of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 C atoms and saturated and / or unsaturated,
  • branched and / or unbranched alcohols of a chain length of 3 to 30 C atoms, from the group of esters of aromatic carboxylic acid and saturated and / or unsaturated, branched and / or
  • ester oils can then be advantageously selected from the group
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C atoms.
  • the fatty acid triglycerides can be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, for. Olive oil, Sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.
  • any mixtures of such oil and wax components are also advantageous to use in the context of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the aqueous phase of the preparations to be used contains
  • alcohols, diols or polyols lower C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, Ethylenglykolmonoethy! or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether,
  • Diethylene glycol monomethyl or monoethyl ether and analogous products furthermore lower C number alcohols, e.g.
  • ethanol isopropanol
  • 1, 2 propanediol 1, 2 propanediol
  • glycerol 1, 2 propanediol
  • thickeners which or which can be advantageously selected from the group
  • Silica aluminum silicates, polysaccharides or their derivatives, e.g. Hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageous from the group of polyacrylates, preferably a polyacrylate from the group of so-called Carbopols, for example Carbopols types 980, 981, 1382, 2984, 5984, each individually or in combination.
  • Carbopols for example Carbopols types 980, 981, 1382, 2984, 5984, each individually or in combination.
  • mixtures of the abovementioned solvents are used.
  • alcoholic solvents water can be another organic solvent.
  • the preparations to be used contain hydrophilic surfactants.
  • the hydrophilic surfactants are preferably selected from the group of alkylglucosides, acyl lactylates, betaines and cocoamphoacetates.
  • emulsifiers for example, the known W / O and O / W emulsifiers can be used. It is advantageous to use other conventional co-emulsifiers in the preferred ⁇ V emulsions.
  • O / W emulsifiers are selected as co-emulsifiers, principally from the group of substances with HLB values of 11-16, very particularly advantageously with HLB values of 14.5-15.5, provided that the O / W Emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value may be those of
  • Emulsifiers also lower or above.
  • Polyethylene glycol (12) isostearate, polyethylene glycol (13) isostearate,
  • Polyethylene glycol (14) isostearate, polyethylene glycol (15) isostearate,
  • Polyethylene glycol (24) isostearate, polyethylene glycol (25) isostearate,
  • the sodium laureth-11-carboxylate can be advantageously used.
  • the alkyl ether sulfate sodium LauretM 4 sulfate can be advantageously used.
  • polyethylene glycol (30) cholesteryl ether can be advantageously used.
  • polyethylene glycol (25) soybean oil has been proven.
  • polyethylene glycol glycerol fatty acid esters from the group of polyethylene glycol (20) glyceryl dilaurate,
  • Polyethylene glycol (20) to choose sorbitan monooleate
  • W / O emulsifiers can be used:
  • W / O emulsifiers are glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate,
  • the preparation may contain cosmetic adjuvants which are commonly used in this type of preparations, e.g.
  • Thickeners emollients, moisturizers,
  • surfactants include emulsifiers, preservatives, antifoaming agents, perfumes, waxes, lanolin, propellants, dyes and / or pigments, and other ingredients commonly used in cosmetics. It is possible to use as dispersion or solubilizing agent an oil, wax or other fatty substance, a low monoalcohol or a low polyol or mixtures thereof. Particularly preferred monoalcohols or polyols include ethanol, i-propanol, propylene glycol, glycerine and sorbitol.
  • B16V mouse melanoma cells (manufacturer: DSMZ, article number: ACC370) are mixed in RPMI medium (Invitrogen, article no .: 31870), which additionally contains 10% FBS (fetal bovine serum; Invitrogen, article no: 10499044 ), 2 mM L-glutamine (Invitrogen, item no: 25030) and 1 mM sodium pyruvate (Invitrogen, item no: 11360) are added and incubated for 72 h at 37 ° C and 5% C0 2 .
  • FBS fetal bovine serum
  • 2 mM L-glutamine Invitrogen, item no: 25030
  • 1 mM sodium pyruvate Invitrogen, item no: 11360
  • the medium is separated and the cells are washed once with 10 ml DPBS (Dulbecco's Phosphate-Buffered Salines, Invitrogen, Item No. 14190) and the medium is then aspirated.
  • 1 ml HyQtase-Cell Detachment Solution (Hyclone, article number SV30030.01) is added to the cells.
  • the bottle is swiveled several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% CO 2.
  • the cells are taken up in the modified RPMI medium (see above) and the number of cells determined.
  • the cells are stained with trypan blue and counted in a Neubauer counting chamber. Subsequently, the cells are seeded again in the modified RPMI medium (see above) in a defined cell number of 80,000 cells per well (6-well Clear Plate, TCT, PS (Nunc)).
  • the cells are incubated for 24 h at 37 ° C. and 5% CO 2, after which the medium is removed. Subsequently, 1980pL of the substance dilution
  • the ethanol extract from Example 1 is dissolved in DMSO and then filtered through a sterile filter (0.2 ⁇ m, Millipore, Article No. SLLG013SL).
  • the solution is then diluted with the modified RPMI medium (see above, but in this case the FBS content is only 5%) such that the final concentration of the extract is 0.1 mg / ml, 0.05 mg / ml and 0, respectively , 01 mg / ml.
  • 20 L of an alpha-MSH solution alpha-melanocyte stimulating hormone, DMSO, Sigma, item no: D2650
  • the mixture is then incubated again for 24 h at 37 ° C and 5% CO2. The process described in this section is repeated twice more.
  • the medium is aspirated and the cells are washed with 1000 ⁇ l DPBS (Invitrogen, Item No. 14190). The medium is sucked off again. It will be 250pL HyQtase Cell
  • Hyclone Item No. SV30030.01
  • Hyclone Item No. SV30030.01
  • the 6-well plate is pivoted several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% C0 2 .
  • the cells are taken up in 1.5mL DPBS (Invitrogen, Item No. 14190) and transferred to a cup (SARSTEDT, Ref. 72.692.005). Subsequently, the cell number is determined. For this, the cells are stained with trypan blue and counted in a Neubauer counting chamber. Centrifuge the cells at 3500g for 1min. The obtained pellets are photographed and
  • the extract also has an inverse concentration dependence with respect to its skin tanning action. He is already effective in very low concentrations.
  • B16V mouse melanoma cells (manufacturer: DSMZ, article number: ACC370) are mixed in RPMI medium (Invitrogen, article no .: 31870), which additionally contains 10% FBS (fetal bovine serum; Invitrogen, article no: 10499044 ), 2 mM L-glutamine (Invitrogen, item no: 25030) and 1 mM sodium pyruvate (Invitrogen, item no: 11360) are added and incubated for 72 h at 37 ° C and 5% C0 2 .
  • FBS fetal bovine serum
  • 2 mM L-glutamine Invitrogen, item no: 25030
  • 1 mM sodium pyruvate Invitrogen, item no: 11360
  • the medium is separated off and the cells are washed once with 10 ml of DPBS (Dulbecco's Phosphate-Buffered Salines, Invitrogen, Article No. 14190) and the medium is subsequently aspirated off.
  • 1 mL of HyQtase-Cell Detachment Solution (Hyclone, Article no. SV30030.01) on the cells.
  • the bottle is swiveled several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% C0 2 .
  • the cells are taken up in the modified RPMI medium (see above) and the number of cells determined.
  • the cells are stained with trypan blue and counted in a Neubauer counting chamber. Subsequently, the cells are seeded again in the modified RPMI medium (see above) in a defined cell number of 80,000 cells per well (6-well Clear Plate, TCT, PS (Nunc)).
  • the cells are incubated for 24 h at 37 ° C. and 5% CO 2, after which the medium is removed. Then 1980 ⁇ _ of the substance dilution
  • the water extract from Example 2 is dissolved in water and then filtered through a sterile filter (0.2 ⁇ m, Millipore, Article No. SLLG013SL).
  • the solution is then diluted with the modified RPMI medium (see above, but in this case the FBS content is only 5%) such that the final concentration of the extract is 0.1 mg / ml, 0.05 mg / ml and 0, respectively , 01 mg / ml.
  • 20 ⁇ _ of an alpha-MSH solution alpha-melanocyte stimulating hormone, DMSO, Sigma, Article No.: D2650
  • the mixture is again incubated at 37 ° for 24 h ° C and 5% CO2
  • the procedure described in this section is repeated twice more.
  • the medium is aspirated and the cells are washed with 1000 ⁇ l DPBS (Invitrogen, Item No. 14 90). The medium is sucked off again. It will be 250pL HyQtase Cell
  • Hyclone Item No. SV30030.01
  • Hyclone Item No. SV30030.01
  • the 6-well plate is pivoted several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% C0 2 .
  • the Cells are picked up in 1.5mL DPBS (Invitrogen, Item No. 14190) and transferred to a cup (SARSTEDT, Ref. 72.692.005). Subsequently, the cell number is determined. For this, the cells are stained with trypan blue and counted in a Neubauer counting chamber. Centrifuge the cells at 3500g for 1min. The obtained pellets are photographed and
  • Example 5 O / W emulsions for skin lightening or
  • Tanning reinforcement data in% by weight
  • phase A is heated to 75 ° C and phase B to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A and stirred until a homogeneous mixture is formed.
  • phase A is heated to 75 ° C and phase B to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A and stirred until a homogeneous mixture is formed.
  • phase A and B are heated to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A and homogenized. It is then cooled and the phase C at 40 ° C was added.
  • phase B is dissolved and then it is given to phase A.
  • phases A and B are mixed separately and heated to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A. It is homogenized cooled to room temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un extrait de parties végétales de Tradescantia virginiana, un procédé pour sa fabrication ainsi que son utilisation dans des préparations cosmétiques et dermatologiques. L'invention concerne en outre des préparations contenant un extrait de parties végétales de Tradescantia virginiana, ainsi qu'un procédé pour leur fabrication.
PCT/EP2012/002894 2011-08-05 2012-07-09 Extraits de tradescantia virginiana WO2013020624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011109522A DE102011109522A1 (de) 2011-08-05 2011-08-05 Extrakte aus Tradescantia virginiana
DE102011109522.9 2011-08-05

Publications (1)

Publication Number Publication Date
WO2013020624A1 true WO2013020624A1 (fr) 2013-02-14

Family

ID=46489170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/002894 WO2013020624A1 (fr) 2011-08-05 2012-07-09 Extraits de tradescantia virginiana

Country Status (2)

Country Link
DE (1) DE102011109522A1 (fr)
WO (1) WO2013020624A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200124019A (ko) * 2019-04-23 2020-11-02 계명대학교 산학협력단 팔리다자주닭개비 추출물을 유효성분으로 포함하는 주름 예방 또는 개선용 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487404A1 (fr) 1990-11-19 1992-05-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition dermatologique externe
WO1993004665A1 (fr) 1991-08-29 1993-03-18 L'oreal Composition cosmetique filtrante contenant un polymere filtre liposoluble a structure hydrocarbonee et une silicone filtre
CN1119938A (zh) * 1995-06-07 1996-04-10 李春锋 一种治疗痤疮皮肤病的化妆品及其生产方法
WO1999009945A1 (fr) * 1997-08-27 1999-03-04 Centre National De La Recherche Scientifique (Cnrs) Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
WO2002047706A2 (fr) * 2000-12-15 2002-06-20 Pharmacia Corporation Inhibition sélective de la cox-2 au moyen d'extraits végétaux
DE10133202A1 (de) 2001-07-07 2003-01-16 Beiersdorf Ag Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE102007042009A1 (de) 2006-10-23 2008-04-24 Acosta Jose Ramon Baez Pharmazeutische Formel zur Behandlung des erworbenen menschlichen Immundefektsyndroms (AIDS) Herstellungsprozess
JP2009040753A (ja) 2007-08-10 2009-02-26 Advangen Inc 皮膚補修組成物及びそれのスクリーニング方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487404A1 (fr) 1990-11-19 1992-05-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition dermatologique externe
WO1993004665A1 (fr) 1991-08-29 1993-03-18 L'oreal Composition cosmetique filtrante contenant un polymere filtre liposoluble a structure hydrocarbonee et une silicone filtre
CN1119938A (zh) * 1995-06-07 1996-04-10 李春锋 一种治疗痤疮皮肤病的化妆品及其生产方法
WO1999009945A1 (fr) * 1997-08-27 1999-03-04 Centre National De La Recherche Scientifique (Cnrs) Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
EP1009378A1 (fr) 1997-08-27 2000-06-21 Centre National De La Recherche Scientifique Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
WO2002047706A2 (fr) * 2000-12-15 2002-06-20 Pharmacia Corporation Inhibition sélective de la cox-2 au moyen d'extraits végétaux
DE10133202A1 (de) 2001-07-07 2003-01-16 Beiersdorf Ag Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE102007042009A1 (de) 2006-10-23 2008-04-24 Acosta Jose Ramon Baez Pharmazeutische Formel zur Behandlung des erworbenen menschlichen Immundefektsyndroms (AIDS) Herstellungsprozess
JP2009040753A (ja) 2007-08-10 2009-02-26 Advangen Inc 皮膚補修組成物及びそれのスクリーニング方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROWN ET AL., PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 63, 2001, pages 148 - 161
C.A. RICE-EVANS; N.J. MILLER; G. PAGANGA, TRENDS IN PLANT SCIENCE, vol. 2, no. 4, 1997, pages 152 - 159
COSMETICS & TOILETRIES, vol. 105, February 1990 (1990-02-01), pages 53 - 64
DATABASE WPI Week 199744, Derwent World Patents Index; AN 1997-471803, XP002685032 *
K. LEMANSKA; H. SZYMUSIAK; B. TYRAKOWSKA; R. ZIELINSKI; 1.M.C.M. RIETJENS, CURRENT TOPICS IN BIOPHYSICS, vol. 24, no. 2, 2000, pages 101 - 108
K. LEMANSKA; H. SZYMUSIAK; B. TYRAKOWSKA; R. ZIELINSKI; A.E.M.F. SOFFERS; 1.M.C.M. RIETJENS, FREE RADICAL BIOLOGY&MEDICINE, vol. 31, no. 7, 2001, pages 869 - 881

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200124019A (ko) * 2019-04-23 2020-11-02 계명대학교 산학협력단 팔리다자주닭개비 추출물을 유효성분으로 포함하는 주름 예방 또는 개선용 조성물
KR102277369B1 (ko) 2019-04-23 2021-07-14 계명대학교 산학협력단 팔리다자주닭개비 추출물을 유효성분으로 포함하는 주름 예방 또는 개선용 조성물

Also Published As

Publication number Publication date
DE102011109522A1 (de) 2013-02-07

Similar Documents

Publication Publication Date Title
EP2648689B1 (fr) 2-pyrones
EP2665717B1 (fr) Dérivés de 7-acyloxy-chromène-4-one et leur utilisation en tant que substances auto-bronzantes
EP2616040B1 (fr) Dérivés 2,2'-furoin et leur utilisation pour eclaircir la peau
WO2012007095A2 (fr) Amplificateur de bronzage et substances auto-bronzantes
EP3522993B1 (fr) Dérivés d'urée monosubstitués utilisés en tant que substance auto-bronzante
EP2720758A2 (fr) EXTRAITS D'EUGENIA UNIFLORA& xA;
EP3402576B1 (fr) Dérivé de noreugénine glycoside
WO2012010242A2 (fr) Substances renforçant le bronzage et substances à effet autobronzant
DE102016011954A1 (de) Barbitursäurederivate als Selbstbräunungssubstanzen
WO2013020624A1 (fr) Extraits de tradescantia virginiana
EP2654687A1 (fr) Dihydroxyacétonemonoéther
EP2709731B1 (fr) Extraits de darlingtonia californica
EP2775996B1 (fr) Utilisation de dérivés de propanol et de propénol en tant qu'antioxydants
EP2640348A2 (fr) Dérivés d'acide dihydroxyfumarique et leur utilisation pour l'éclaircissement de la peau
EP2600854B1 (fr) Dérivés de phényléthyle, de phényléthylène, de phényléthyne et d'indanone dans des préparations cosmétiques, notamment utilisées pour lutter contre des processus de vieillissement de la peau
EP2846765A2 (fr) Dérivés de phénylcétone en tant qu'autobronzants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12733427

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12733427

Country of ref document: EP

Kind code of ref document: A1